pharma · Rheumatoid Arthritis · Calcium
Universal Integrated
Universal Integrated patent portfolio — 42 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- HILLSIDE, NJ, CN
- Founded
- 2006
- Employees
- 304
- Programs
- 89
- Drugs
- 105
- Patents
- 42
Universal Integrated patents
42 pharmaceutical patents indexed for Universal Integrated. 1 expire within 24 months.
Universal Integrated has 42 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 1 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12076377
Variant sulfatase enzymes with enhanced properties
granted -
US 11421021
Immunogenic compositions comprising Staphylococcus aureus leukocidin LukA and LukB derived polypeptides
granted -
US 11260120
Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
granted -
US 11186626
Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop
granted -
US 11154614
Method for producing virus like particles
granted -
US 11135280
Modified ebolavirus glycoproteins comprising mutations in the head and base domains that increase antibody cross-reactivity
granted -
US 11028153
Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
granted -
US 10653800
Oligonucleotide-based probes for detection of bacterial nucleases
granted -
US 10611827
Non-human primate-derived pan-ebola and pan-filovirus monoclonal antibodies directed against envelope glycoproteins
granted -
US 10487140
Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
granted -
US 10233450
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 10174085
Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
granted -
US 10106792
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 10023848
Immunogenic composition comprising Panton-Valentine Leukocidin (PVL) derived polypeptides
granted -
US 9988630
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 9873875
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 9815872
Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
granted -
US 9603949
Oligonucleotide-based probes for detection of bacterial nucleases
granted -
US 9518262
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 9441227
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 9365849
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 9109036
Immunogenic composition comprising alpha-hemolysin oligopeptides
granted -
US 8883996
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 8809515
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 8796444
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 8691786
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 8658356
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 8586006
Organ-specific proteins and methods of their use
granted -
US 8507650
Use of bacteriophage outer membrane breaching proteins expressed in plants for the control of gram-negative bacteria
granted -
US 8212110
Use of bacteriophage outer membrane breaching proteins expressed in plants for the control of gram-negative bacteria
granted -
US 8084599
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 7537791
Parthenolide free bioactive ingredients from feverfew (Tanacetum parthenium) and processes for their production
granted -
US 7473435
Bioactive compositions form Theacea plants and processes for their production and use
granted -
US 7465466
Compositions and methods for prostate and kidney health and disorders, an herbal preparation
granted -
US 7449202
Compositions and methods for prostate and kidney health and disorders, an herbal preparation
granted -
US 7442391
Bioactive botanical cosmetic compositions and processes for their production
granted -
US 7223424
Compositions and methods for prostate and kidney health and disorders, an herbal preparation
granted -
US 6891989
Optical switch systems using waveguide grating-based wavelength selective switch modules
expired -
US 6879754
Drop-before-add optical switching and routing system employing grating-based wavelength selective switches
expired -
US 6855344
Compositions and methods for prostate and kidney health and disorders, an herbal preparation
expired -
US 6608715
Wavelength converter using Bragg-grating
expired -
US 6242486
Long chain carboxybetaines in antimicrobial formulations
expired
Frequently asked questions
How many patents does Universal Integrated have?
42 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Universal Integrated patents expire?
1 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.